Can Intellia's Pipeline Push Drive Long-Term Growth Amid Rivalry?
NTLA advances late-stage studies for nex-z and starts FDA filing for lonvo-z, positioning its pipeline for potential long-term growth.
NTLA - Intellia Therapeutics, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$26.29
DETAILS
HIGH:
$49.00
LOW:
$13.00
MEDIAN:
$25.00
CONSENSUS:
$26.29
UPSIDE:
108.65%
Stock News
Intellia Therapeutics, Inc. (NTLA) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Intellia Therapeutics, Inc. (NTLA) Presents at Bank of America Global Healthcare Conference 2026 Transcript
NTLA Q1 Earnings Beat Estimates, Revenues Miss Mark, Pipeline in Focus
Intellia cuts its Q1 loss, advances late-stage gene-editing programs and plans a 2027 launch for lonvo-z after strong phase III HAE data.
Intellia Therapeutics, Inc. (NTLA) Reports Q1 Loss, Misses Revenue Estimates
Intellia Therapeutics, Inc. (NTLA) came out with a quarterly loss of $0.81 per share versus the Zacks Consensus Estimate of a loss of $0.92. This compares to a loss of $1.1 per share a year ago.
Intellia Therapeutics Announces First Quarter 2026 Financial Results and Business Updates
CAMBRIDGE, Mass., May 11, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today reported business updates and financial results for the first quarter ended March 31, 2026.
Intellia Therapeutics Announces First Quarter 2026 Financial Results and Business Updates
Presented positive Phase 3 HAELO topline clinical data for lonvo-z in HAE; initiated rolling BLA submission; anticipate U. S. launch in first half of 2027 Recently resumed patient screening in MAGNITUDE and MAGNITUDE-2 Phase 3 clinical trials of nex-z in ATTR-CM and ATTRv-PN, respectively Including proceeds from underwritten public offering in April, existing cash resources expected to fund operations at least into 2028 CAMBRIDGE, Mass.
Intellia Therapeutics, Inc. (NTLA) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Intellia Therapeutics (NTLA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
One of these stocks plummeted 49% on Tuesday.
Intellia Therapeutics to Participate in Upcoming Investor Conferences
CAMBRIDGE, Mass., May 05, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced that management will be participating in fireside chats at the following upcoming investor conferences:
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., May 01, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced that on May 1, 2026, it awarded inducement grants to 43 new employees under Intellia's 2024 Inducement Plan, as amended, as a material inducement to employment.
Intellia Therapeutics Posts Phase 3 HAELO Win for lonvo-z, Begins Rolling FDA BLA Filing
Intellia Therapeutics (NASDAQ: NTLA) highlighted top-line results from its Phase III HAELO trial evaluating lonvo-z, an investigational in vivo CRISPR-based gene-editing therapy for hereditary angioedema (HAE), and provided an update on regulatory progress during a company conference call. Company outlines lonvo-z strategy and HAE unmet need Chief Executive Officer John Leonard described the update as a
Intellia Therapeutics Announces Pricing of Public Offering of Common Stock
CAMBRIDGE, Mass., April 29, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced the pricing of an underwritten public offering of 16,744,187 shares of its common stock. The shares of common stock are being sold at a public offering price of $10.75 per share. The gross proceeds from the offering, before deducting underwriting discounts and commissions and offering expenses, are expected to be approximately $180 million, excluding any exercise of the underwriters' option to purchase additional shares. All of the securities in the offering are to be sold by Intellia. In addition, Intellia has granted the underwriters a 30-day option to purchase up to 2,511,628 additional shares of its common stock at the public offering price, less the underwriting discounts and commissions.
Cathie Wood just made a massive bet on these two top AI stocks
While the heyday of Cathie Wood's investment management is, for the time being, firmly in the past, the popular ARK Innovation ETF (ARKK) has been having a respectable run in the last 12 months and unveiled its latest series of bets as recently as April 28.
NTLA Falls 4% Despite Strong Phase III HAE Data, Initiates Rolling BLA
Intellia shares drop 4% despite phase III data meeting all endpoints. The company begins a rolling FDA filing.
Intellia Announces Proposed Public Offering of Common Stock
CAMBRIDGE, Mass., April 27, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced that it has commenced an underwritten public offering of $150 million of shares of its common stock. Intellia also intends to grant the underwriters a 30-day option to purchase up to an additional fifteen percent (15%) of the shares of common stock offered in the public offering. All of the shares in the proposed offering are to be sold by Intellia.
Intellia Therapeutics, Inc. (NTLA) Discusses Topline Phase 3 HAELO Trial Results for Lonvoguran Ziclumeran in Hereditary Angioedema Transcript
Intellia Therapeutics, Inc. (NTLA) Discusses Topline Phase 3 HAELO Trial Results for Lonvoguran Ziclumeran in Hereditary Angioedema Transcript
Wall Street on Edge Ahead of Next U.S.-Iran Development
Stocks are lower across the board, as investors await the latest U.S.-Iran developments and monitor oil prices
Intellia Therapeutics FDA Rolling Application For Gene Therapy Puts Hype To Test
Intellia Therapeutics Inc. (NASDAQ:NTLA) shares are up on Monday after the company announced a rolling BLA submission to the FDA for its gene-editing therapy, lonvo-z (NTLA-2002), which is aimed at treating hereditary angioedema.
Stock Futures Subdued by Geopolitical Uncertainty
Stock futures are struggling this morning as investors await Magnificent Seven earnings and the Fed meeting
Intellia Therapeutics' rare genetic disorder therapy meets main goal in trial
Intellia Therapeutics said on Monday its experimental therapy for a rare genetic disorder has met the main goal in a late-stage study.
Price Targets
Intellia Therapeutics price target raised to $17 from $13 at Bernstein
$17.00
(was $13.99)
Bernstein
Intellia Therapeutics price target lowered to $49 from $58 at Canaccord
$49.00
(was $14.42)
Canaccord Genuity
Intellia Therapeutics price target raised to $30 from $27 at Chardan
$30.00
(was $13.03)
Chardan Capital
Intellia Therapeutics price target raised to $35 from $29 at Leerink
$35.00
(was $13.21)
Leerink Partners
Intellia Therapeutics price target raised to $15 from $11 at Morgan Stanley
$15.00
(was $14.07)
Morgan Stanley
Intellia Therapeutics price target raised to $13 from $7 at Baird
$13.00
(was $13.94)
Jack Allen
·
Robert W. Baird
Intellia Therapeutics (NTLA) PT Raised to $25 at H.C. Wainwright
$25.00
(was $13.95)
KeyBanc
Intellia Therapeutics (NTLA) PT Raised to $7 at Baird
$7.00
(was $14.39)
Jack Allen
·
Robert W. Baird
Intellia Therapeutics downgraded to In Line from Outperform at Evercore ISI
$8.00
(was $9.73)
Evercore ISI
Intellia Therapeutics price target lowered to $14 from $25 at Truist
$14.00
(was $9.91)
Truist Financial
Intellia Therapeutics price target lowered to $27 from $33 at Oppenheimer
$27.00
(was $9.87)
Oppenheimer
Intellia Therapeutics price target lowered to $9 from $14 at Wedbush
$9.00
(was $12.49)
David Nierengarten
·
Wedbush
Intellia Therapeutics price target lowered to $18 from $25 at H.C. Wainwright
$18.00
(was $13.12)
Mitchell Kapoor
·
H.C. Wainwright
Intellia Therapeutics (NTLA) PT Lowered to $9 at Baird
$9.00
(was $13.12)
Jack Allen
·
Robert W. Baird
Intellia Therapeutics price target lowered to $29 from $33 at Citizens JMP
$29.00
(was $14.79)
JMP Securities
Intellia Therapeutics downgraded to Market Perform from Outperform at Bernstein
$14.50
(was $14.79)
Bernstein
Intellia Therapeutics price target lowered to $24 from $26 at Barclays
$24.00
(was $14.79)
Gena Wang
·
Barclays
Bernstein SocGen Group Downgrades Intellia Therapeutics (NTLA) to Market Perform
$14.50
(was $14.79)
William Pickering
·
Tudor Pickering
RBC Capital Downgrades Intellia Therapeutics (NTLA) to Sector Perform
$14.00
(was $14.79)
Luca Issi
·
RBC Capital
Intellia Therapeutics price target lowered to $48 from $60 at Chardan
$48.00
(was $25.60)
Chardan Capital